| Basics |
Cytokinetics, Incorporated
Cytokinetics Inc is a biopharmaceutical company. It is engaged in the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions.
|
| IPO Date: |
May 1, 2004 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$3.79B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.39 | 2.83%
|
| Avg Daily Range (30 D): |
$1.07 | 2.91%
|
| Avg Daily Range (90 D): |
$1.09 | 2.60%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.55M |
| Avg Daily Volume (30 D): |
2.17M |
| Avg Daily Volume (90 D): |
1.66M |
| Trade Size |
| Avg Trade Size (Sh.): |
110 |
| Avg Trade Size (Sh.) (30 D): |
68 |
| Avg Trade Size (Sh.) (90 D): |
66 |
| Institutional Trades |
| Total Inst.Trades: |
6,982 |
| Avg Inst. Trade: |
$3.23M |
| Avg Inst. Trade (30 D): |
$2.63M |
| Avg Inst. Trade (90 D): |
$2.99M |
| Avg Inst. Trade Volume: |
.08M |
| Avg Inst. Trades (Per Day): |
4 |
| Market Closing Trades |
| Avg Closing Trade: |
$6.54M |
| Avg Closing Trade (30 D): |
$8.45M |
| Avg Closing Trade (90 D): |
$10.14M |
| Avg Closing Volume: |
168.83K |
|
|
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q3 2024 |
|
Basic EPS
|
|
$-1.36
|
$-1.36
|
|
Diluted EPS
|
|
$-1.36
|
$-1.36
|
|
Revenue
|
$
|
$ 1.58M
|
$ .46M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$
|
$ -161.38M
|
$ -160.55M
|
|
Operating Income / Loss
|
$
|
$ -155.63M
|
$ -140.8M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$
|
$ -21.18M
|
$ -143.25M
|
|
PE Ratio
|
|
|
|
|
